Got $300? 2 Biotech Stocks to Buy and Hold Forever

These two biotechs only have one marketable therapy each, but both have blockbuster potential.Krystal Biotech (KRYS +2.29%) and ARS Pharmaceuticals (SPRY +0.45%) have been gaining a lot of attention over the past year, thanks to the potential in their groundbreaking -- and for now, only -- commercial therapies.In 2023, Krystal pioneered Vyjuvek, the first topical genetic therapy and first treatment approved by the Food and Drug Administration (FDA) for dystrophic epidermolysis bullosa, a rare skin disorder. ...